Last reviewed · How we verify
tumor-specific TCR-T cells
At a glance
| Generic name | tumor-specific TCR-T cells |
|---|---|
| Also known as | TCR-T cells, FIT-001 |
| Sponsor | Guangzhou FineImmune Biotechnology Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (PHASE2)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (PHASE2)
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) (PHASE3)
- HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer (PHASE1)
- A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tumor-specific TCR-T cells CI brief — competitive landscape report
- tumor-specific TCR-T cells updates RSS · CI watch RSS
- Guangzhou FineImmune Biotechnology Co., LTD. portfolio CI